UNICA IRIS Institutional Research Information System

MORELLI, MICAELA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 251.427
NA - Nord America 22.987
AS - Asia 7.810
SA - Sud America 1.340
Continente sconosciuto - Info sul continente non disponibili 818
AF - Africa 179
OC - Oceania 13
Totale 284.574
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 246.818
US - Stati Uniti d'America 22.579
SG - Singapore 3.023
CN - Cina 2.817
UA - Ucraina 1.490
BR - Brasile 1.053
SE - Svezia 845
VN - Vietnam 713
DE - Germania 528
FI - Finlandia 518
GB - Regno Unito 482
FR - Francia 387
HK - Hong Kong 314
CA - Canada 218
IN - India 177
KR - Corea 172
AR - Argentina 101
BD - Bangladesh 99
MX - Messico 73
RU - Federazione Russa 67
IQ - Iraq 66
JP - Giappone 63
ZA - Sudafrica 52
EC - Ecuador 46
ID - Indonesia 45
TR - Turchia 45
CO - Colombia 43
PK - Pakistan 41
ES - Italia 38
NL - Olanda 37
PL - Polonia 34
JM - Giamaica 32
BE - Belgio 28
IL - Israele 28
SA - Arabia Saudita 25
VE - Venezuela 24
MA - Marocco 23
PH - Filippine 22
CL - Cile 21
EG - Egitto 21
AT - Austria 20
IE - Irlanda 20
TN - Tunisia 19
MY - Malesia 18
UZ - Uzbekistan 18
EU - Europa 17
LT - Lituania 17
KE - Kenya 16
PY - Paraguay 16
CR - Costa Rica 15
PE - Perù 15
AE - Emirati Arabi Uniti 14
CZ - Repubblica Ceca 14
ET - Etiopia 14
TH - Thailandia 13
AZ - Azerbaigian 12
GT - Guatemala 11
NP - Nepal 11
RO - Romania 11
UY - Uruguay 11
AU - Australia 10
HN - Honduras 10
JO - Giordania 10
AL - Albania 9
BO - Bolivia 9
NI - Nicaragua 9
SV - El Salvador 9
TT - Trinidad e Tobago 9
DZ - Algeria 8
KZ - Kazakistan 8
OM - Oman 8
PT - Portogallo 8
TW - Taiwan 8
CH - Svizzera 7
BY - Bielorussia 6
GE - Georgia 6
IR - Iran 6
BB - Barbados 5
DO - Repubblica Dominicana 5
MN - Mongolia 5
MU - Mauritius 5
NO - Norvegia 5
AO - Angola 4
BG - Bulgaria 4
DK - Danimarca 4
HU - Ungheria 4
NG - Nigeria 4
PS - Palestinian Territory 4
BA - Bosnia-Erzegovina 3
BH - Bahrain 3
CI - Costa d'Avorio 3
EE - Estonia 3
HR - Croazia 3
KG - Kirghizistan 3
LB - Libano 3
MD - Moldavia 3
QA - Qatar 3
RS - Serbia 3
SC - Seychelles 3
SI - Slovenia 3
Totale 283.735
Salva come PNG Salva come JPEG
Città #
Cagliari 239.987
Uta 5.888
Fairfield 2.330
Ashburn 2.302
Woodbridge 1.633
Singapore 1.512
Chandler 1.274
San Jose 1.224
Houston 1.110
Seattle 949
Wilmington 922
Ann Arbor 849
Dallas 840
Boardman 820
Jacksonville 804
Cambridge 757
Nyköping 508
Beijing 494
Council Bluffs 400
Los Angeles 351
Dearborn 317
New York 282
Hong Kong 279
Helsinki 273
Nanjing 272
Santa Clara 245
Lauterbourg 227
Hefei 223
Boston 211
Ho Chi Minh City 211
Seoul 162
The Dalles 161
Shanghai 159
Hanoi 141
Buffalo 137
San Diego 136
Hangzhou 113
São Paulo 108
Milan 104
Toronto 95
Shenyang 89
Redwood City 78
Chicago 77
Hebei 73
Dong Ket 70
London 69
Guangzhou 67
Nanchang 63
Changsha 59
Mountain View 59
Munich 58
Redondo Beach 57
Rome 57
Brooklyn 55
Atlanta 52
Verona 52
Jiaxing 49
Tianjin 48
Columbus 46
Phoenix 45
Tokyo 44
Norwalk 43
Frankfurt am Main 41
Washington 41
Jinan 40
Da Nang 39
Montreal 39
Orem 36
Zhengzhou 35
Haiphong 31
Rio de Janeiro 31
Sassari 30
Auburn Hills 29
San Francisco 28
Chennai 27
Orange 26
Baghdad 25
Mexico City 24
Brussels 23
Ningbo 23
North Bergen 23
Brasília 22
Curitiba 20
Newark 20
Warsaw 20
Belo Horizonte 19
Denver 19
Falls Church 19
Nuremberg 19
Johannesburg 18
Manchester 18
Pune 18
Queens 18
Kingston 17
Paris 17
Porto Alegre 17
Charlotte 16
Dhaka 16
Miami 16
Stockholm 16
Totale 271.056
Salva come PNG Salva come JPEG
Nome #
Effect of memantine on L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson's disease. 4.361
Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease 4.310
Odor identification performance in idiopathic Parkinson’s disease is associated with gender and the genetic variability of the olfactory binding protein 3.717
Pharmacological characterization of 50-kHz ultrasonic vocalizations in rats: comparison of the effects of different psychoactive drugs and relevance in drug-induced reward 3.670
Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson's disease 3.566
Role of Adenosine in the basal Ganglia 3.380
Antagonism of Adenosine A1 or A2A Receptors Amplifies the Effects of 3,4-Methylendioxymethamphetamine (MDMA) on Glial Activation in the Mouse Brain: Relevance to Caffeine-MDMA Interactions 3.153
Amphetamine-related drugs neurotoxicity in humans and in experimental animals: Main mechanisms 3.052
Elevation of striatal urate in experimental models of Parkinson's disease: a compensatory mechanism triggered by dopaminergic nigrostriatal degeneration? 3.037
Protective Agents in Parkinson's Disease: Caffeine and Adenosine A2A Receptor Antagonists 2.955
Vitamin A deficiency induces motor impairments and striatal cholinergic dysfunction in rats 2.890
Direct and long-lasting effects elicited by repeated drug administration on 50-kHz ultrasonic vocalizations are regulated differently: Implications for the study of the affective properties of drugs of abuse 2.864
Modulation of rat 50-kHz ultrasonic vocalizations by glucocorticoid signaling: possible relevance to reward and motivation 2.852
Role of adenosine A2A receptors in motor control: relevance to Parkinson’s disease and dyskinesia 2.804
Late-onset Parkinsonism in NFκB/c-Rel-deficient mice 2.803
Effect of crowding, temperature and age on glia activation and dopaminergic neurotoxicity induced by MDMA in the mouse brain 2.746
Methylxanthines and drug dependence: interactions and toxicity 2.741
MPTP-induced dopamine neuron degeneration and glia activation is potentiated in MDMA pretreated mice 2.727
Symptomatic and Neuroprotective Effects of A2A Receptor Antagonists in Parkinson’s Disease 2.699
Influence of caffeine on 3,4-methylenedioxymethamphetamine-induced dopaminergic neuron degeneration and neuroinflammation is age-dependent 2.695
Novel (Hetero)arylalkenyl propargylamine compounds are protective in toxin-induced models of Parkinson's disease 2.654
Microglial and astroglial activation by 3,4-methylenedioxymethamphetamine (MDMA) in mice depends on S(+) enantiomer and is associated with an increase in body temperature and motility 2.564
Progression and Persistence of Neurotoxicity Induced by MDMA in Dopaminergic Regions of the Mouse Brain and Association with Noradrenergic, GABAergic, and Serotonergic Damage 2.550
Repeated Administration of 3,4-Methylenedioxymethamphetamine (MDMA) Elevates the Levels of Neuronal Nitric Oxide Synthase in the Nigrostriatal System: Possible Relevance to Neurotoxicity 2.546
Influence of dopamine transmission in the medial prefrontal cortex and dorsal striatum on the emission of 50-kHz ultrasonic vocalizations in rats treated with amphetamine: Effects on drug-stimulated and conditioned calls 2.542
Assessment of symptomatic and neuroprotective efficacy of Mucuna pruriens seed extract in rodent model of Parkinson's disease 2.535
Lack of Rhes Increases MDMA-Induced Neuroinflammation and Dopamine Neuron Degeneration: Role of Gender and Age 2.490
Involvement of Glutamate NMDA Receptors in the Acute, Long-Term, and Conditioned Effects of Amphetamine on Rat 50kHz Ultrasonic Vocalizations 2.458
Rhes counteracts dopamine neuron degeneration and neuroinflammation depending on gender and age 2.434
Activation of adenosine A2A receptors suppresses the emission of pro-social and drug-stimulated 50-kHz ultrasonic vocalizations in rats: possible relevance to reward and motivation 2.427
The Small GTP-Binding Protein Rhes Influences Nigrostriatal-Dependent Motor Behavior During Aging 2.414
Gut Microbiota and Metabolome Alterations Associated with Parkinson’s Disease 2.413
Genetic variants of TAS2R38 bitter taste receptor associate with distinct gut microbiota traits in Parkinson's disease: A pilot study 2.410
A critical evaluation of behavioral rodent models of motor impairment used for screening of antiparkinsonian activity: The case of adenosine A2A receptor antagonists 2.335
MDMA administration during adolescence exacerbates MPTP-induced cognitive impairment and neuroinflammation in the hippocampus and prefrontal cortex 2.299
null 2.277
Contribution of Caffeine to the Psychostimulant, Neuroinflammatory and Neurotoxic Effects of Amphetamine-Related Drugs 2.258
Caffeine Enhances Astroglia and Microglia Reactivity Induced by 3,4-Methylenedioxymethamphetamine (‘Ecstasy’) in Mouse Brain 2.193
Performance of movement in hemiparkinsonian rats influences the modifications induced by dopamine agonists in striatal efferent dynorphinergic neurons 2.142
A new ethyladenine antagonist of adenosine A(2A) receptors: behavioral and biochemical characterization as an antiparkinsonian drug 2.126
Dyskinetic potential of dopamine agonists is associated with different striatonigral/striatopallidal zif-268 expression 2.112
NCX1 and NCX3 as potential factors contributing to neurodegeneration and neuroinflammation in the A53T transgenic mouse model of Parkinson's Disease 2.041
Repeated amphetamine administration and long-term effects on 50-kHz ultrasonic vocalizations: possible relevance to the motivational and dopamine-stimulating properties of the drug 2.011
Preface [ to The Adenosinergic System. A Non-Dopaminergic Target in Parkinson’s Disease] 2.001
Neurochemical and neurotoxic effects of MDMA (Ecstasy) and caffeine after chronic combined administration in mice 1.990
Role of movement in long-term basal ganglia changes: implications for abnormal motor responses 1.982
Metformin prevented dopaminergic neurotoxicity induced by 3,4-Methylenedioxymethamphetamine administration 1.943
Alteration in the progression of dopamine neuron degeneration: May caffeine offer new perspective? 1.896
Gender Differences in Neurodegeneration, Neuroinflammation and Na+-Ca2+ Exchangers in the Female A53T Transgenic Mouse Model of Parkinson’s Disease 1.871
Neuroinflammation and activation of Zif-268 in dyskinetic 6-OHDA-lesioned rats is counteracted by association of a 5-HT1A/1B receptor agonist and an A2A receptor antagonist 1.867
Farmaci antiparkinsoniani ed attivi in altri disturbi motori 1.860
Combined administration of dopaminergic and nondopaminergic drugs reverses neuroinflammation in a rat model of Parkinson’s disease 1.849
Increased emissions of 50-kHz ultrasonic vocalizations in hemiparkinsonian rats repeatedly treated with dopaminomimetic drugs: A potential preclinical model for studying the affective properties of dopamine replacement therapy in Parkinson's disease 1.849
Caffeine consumption and changes in the function of dopaminergic transmission: evidence of a hyperdopaminergic state in rats subchronically treated with caffeine 1.830
Dyskinesia in Parkinson's disease: mechanisms and current non-pharmacological interventions 1.817
Behavioral, neurochemical, and electrophysiological changes in an early spontaneous mouse model of nigrostriatal degeneration 1.815
Decreased Rhes mRNA levels in the brain of patients with Parkinson’s disease and MPTP-treated macaques 1.743
Neuroprotective and anti-inflammatory effects of the adenosine A(2A) receptor antagonist ST1535 in a MPTP mouse model of Parkinson's disease. 1.717
Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6-OHDA lesioned rat 1.677
Antiparkinsonian actions and interactions of adenosine antagonists 1.669
null 1.651
The small GTP-binding protein Rhes influences midbrain dopaminergic neurons: Behavioral and biochemical studies 1.631
Farmaci utilizzati nella terapia della Malattia di Parkinson e di altri disturbi motori 1.572
Withania somnifera influences MDMA-induced hyperthermic, cognitive, neurotoxic and neuroinflammatory effects in mice 1.571
Gender-dependent behavioral and biochemical differences in the A53T genetic mouse model of Parkinson’s disease 1.488
Effect of caffeine on 3,4- methylenedioxymethamphetamine-induced neuroinflammation in mouse brain 1.437
Adenosine signaling in the basal ganglia 1.320
Blockade of globus pallidus adenosine A2A receptors displays antiparkinsonian activity in 6-hydroxydopamine-lesioned rats treated with D1 or D2 dopamine receptor agonists 1.309
Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: acute and subchronic studies in rats 1.304
Effect of caffeine on 3, 4 – methylenedioxymethamphetamine – induced astroglia and microglia activation in mouse brain 1.303
Acute perinatal asphyxia impairs non-spatial memory and alters motor coordination in adult male rats 1.226
The 6-hydroxydopamine model of Parkinson's disease 1.203
Adenosine A2A and dopamine receptor interactions in basal ganglia of dopamine denervated rats 1.201
null 1.194
Direct and indirect striatal efferent pathways are differentially influenced by low and high dyskinetic drugs: behavioural and biochemical evidence 1.189
Inactivation of neuronal forebrain A receptors protects dopaminergic neurons in a mouse model of Parkinson's disease 1.185
In utero exposure to dexamethasone causes a persistent and age-dependent exacerbation of the neurotoxic effects and glia activation induced by MDMA in dopaminergic brain regions of C57BL/6J mice 1.165
Adenosine A2A receptor antagonist treatment of Parkinson’s disease 1.150
Adenosine A2A receptor antagonists and Parkinson’s disease: state of the art and future directions 1.150
Function of dopamine in the extrapyramidal and limbic systems 1.142
A preclinical study on the combined effects of repeated eltoprazine and preladenant treatment for alleviating L-DOPA-induced dyskinesia in Parkinson's disease 1.124
A2A receptor antagonism and dyskinesia in Parkinson’s Disease 1.123
6-n-propylthiouracil taste disruption and TAS2R38 nontasting form in Parkinson's disease 1.119
null 1.108
Synthesis of ibuprofen heterocyclic amides and investigation of their analgesic and toxicological properties 1.105
Caffeine Consumption and Changes in the Function of Dopaminergic Transmission: Evidence of a Hyperdopaminergic State in Rats Subchronically Treated with Caffeine 1.101
Adenosine A2A receptors and Parkinson's disease 1.085
Anxyiolytic properties of a 2-phenylindolglyoxylamide TSPO ligand: Stimulation of in vitro neurosteroid production affecting GABAA receptor activity 1.057
Methylxanthines and Drug Dependence: A Focus on Interactions with Substances of Abuse 1.044
Impulse control disorders and dopamine dysregulation syndrome associated with dopamine agonist therapy in Parkinson's disease 1.035
Activation of Antioxidant and Proteolytic Pathways in the Nigrostriatal Dopaminergic System After 3,4-Methylenedioxymethamphetamine Administration: Sex-Related Differences 1.025
null 1.012
Changes in the expression of tonic and phasic neurochemical markers of activity in a rat model of L-DOPA induced dyskinesia 996
Effects of docosanyl ferulate, a constituent of Withania somnifera, on ethanol- and morphine-elicited conditioned place preference and ERK phosphorylation in the accumbens shell of CD1 mice 994
Differential effect of MK 801 and scopolamine on c-fos expression induced by L-dopa in the striatum of 6-hydroxydopamine lesioned rats 987
Protective Agents in Parkinson’s Disease: Caffeine and Adenosine A2A Receptor Antagonists 987
null 981
Birth asphyxia as the major complication in newborns: Moving towards improved individual outcomes by prediction, targeted prevention and tailored medical care 977
Changes in the expression of tonic and phasic neurochemical markers of activity in a rat model of L-DOPA induced dynskinesia 970
null 967
Totale 195.817
Salva come PNG Salva come JPEG
Categoria #
all - tutte 404.378
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 404.378
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202210.230 0 0 0 806 878 1.004 1.109 716 832 1.321 1.539 2.025
2022/202321.093 1.985 2.506 1.915 1.779 1.902 2.223 1.052 1.816 1.484 1.548 1.991 892
2023/202424.574 1.019 971 1.077 1.426 2.404 4.033 3.710 1.751 1.002 2.055 2.489 2.637
2024/202537.231 5.784 7.130 6.779 5.143 2.705 3.688 3.579 324 599 466 468 566
2025/202617.131 955 742 1.753 1.447 1.083 977 4.995 1.016 1.044 1.446 1.107 566
2026/20274.704 471 961 1.852 1.420 0 0 0 0 0 0 0 0
Totale 284.574